UniQure

UniQure is a biotechnology company that develops gene therapies for severe genetic diseases, including its lead candidate for Huntington's disease.

Why it’s in the news: It is in the news due to its ongoing clinical data for its Huntington's gene therapy and its recent regulatory dispute with the FDA.

Latest on UniQure

• STAT+: Why a Huntington’s patient isn’t fazed by the waning effect of UniQure’s gene therapy
• STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years
• STAT+: What to expect from UniQure’s upcoming Huntington’s gene therapy readout
• FDA Reversal On uniQure Gene Therapy Is Another Sign Of Renewed Regulatory Flexibility
• STAT+: Following dispute with FDA, UniQure is cleared to submit Huntington’s treatment for approval

Connections

4 entities linked to UniQure across the news graph.